Final LATITUDE Results Confirm Previous Findings for High-Risk Prostate Cancer

Final results of LATITUDE confirm the beneft of abiraterone acetate plus prednisone along with ADT in high-risk metastatic castration-sensitive prostate cancer.

Source: CancerNetwork - May 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news